VRAX (Virax Biolabs Group) Debt-to-Asset : 0.06 (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Debt-to-Asset?

Virax Biolabs Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.09 Mil. Virax Biolabs Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.29 Mil. Virax Biolabs Group's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was $6.43 Mil. Virax Biolabs Group's debt to asset for the quarter that ended in Mar. 2025 was 0.06.

Virax Biolabs Group Debt-to-Asset Historical Data

The historical data trend for Virax Biolabs Group's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Debt-to-Asset Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.04

0.06

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial						0.02	0.03	0.04	0.04	0.06

Competitive Comparison of Virax Biolabs Group's Debt-to-Asset

For the Biotechnology subindustry, Virax Biolabs Group's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Virax Biolabs Group Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Virax Biolabs Group's Debt-to-Asset for the fiscal year that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.085	+	0.292)	/	6.427
	=	0.06

Virax Biolabs Group's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.085	+	0.292)	/	6.427
	=	0.06

Virax Biolabs Group (NAS:VRAX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Virax Biolabs Group Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.